"We continue to execute very well on our projects," continued Dr. McKelvey. "We completed the integration of the CCSS acquisition, which was a tremendous accomplishment by our staff. Our sales force reports a healthy pipeline of new opportunities, reflecting the continued emphasis on cardiac safety and eRT's reputation for quality, medical and scientific leadership, project execution, and technology innovation. The pricing environment continues to be stable. In the current economic and financial environment, we feel that our strong balance sheet and cash flow, the continued importance of cardiac safety in clinical trials, and our established reputation for quality, project management, and cost-effective performance will be important contributors to our business going forward."
The Company issued guidance for the full year and fourth quarter of 2008. For the full year 2008, the Company is narrowing its revenue range and expects revenue of between $134.0 million and $137.0 million. The company is raising its guidance for diluted net income per share to between $0.47 to $0.50 for the full year 2008. The company's revenue guidance for the fourth quarter is between $31.0 to $34.0 million, and its guidance for diluted net income per share for the fourth quarter is between $0.10 and $0.13.
Dr. McKelvey and Keith Schneck, the Company's Chief Financial Officer,
will hold a conference call to discuss these results. The conference call
will take place at 5:00 p.m. EDT on October 30, 2008. Interested
participants should call 1-866-277-1181 when calling within the United
States or 617-597- 5358 when calling internationally. Please use pass code
54904519. There wil
|SOURCE eResearchTechnology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved